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Background: The results of preclinical studies suggest that baclofen may be useful in the treatment of stroke
patients with persistent hiccups. This study was aimed to assess the possible efficacy of baclofen for the treatment
of persistent hiccups after stroke.
Methods: In total, 30 stroke patients with persistent hiccups were randomly assigned to receive baclofen (n = 15)
or a placebo (n = 15) in a double-blind, parallel-group trial. Participants in the baclofen group received 10 mg
baclofen 3 times daily for 5 days. Participants assigned to the placebo group received 10 mg placebo 3 times daily
for 5 days. The primary outcome measure was cessation of hiccups. Secondary outcome measures included efficacy
in the two groups and adverse events.
Results: All 30 patients completed the study. The number of patients in whom the hiccups completely stopped
was higher in the baclofen group than in the placebo group (relative risk, 7.00; 95% confidence interval, 1.91–25.62;
P = 0.003). Furthermore, efficacy was higher in the baclofen group than in the placebo group (P < 0.01). No serious
adverse events were documented in either group. One case each of mild transient drowsiness and dizziness was
present in the baclofen group.
Conclusions: Baclofen was more effective than a placebo for the treatment of persistent hiccups in stroke patients.
Trial registration: Chinese Clinical Trials Register: ChiCTR-TRC-13004554
Keywords: Baclofen, Stroke, Hiccups: Randomized controlled trialBackground
Hiccups are caused by involuntary multiple spastic con-
tractions of the diaphragm and intercostal muscles. This
action is rapidly accompanied with uncontrollable inha-
lation and a sudden closure of the respiratory tract by
the epiglottis, resulting in the classic “hic” sound [1,2].
Episodes of hiccups often start with sudden inspiration
and end with abrupt closure of the glottis. Although hic-
cups are thought to develop through the hiccup reflex
arc, the pathophysiology of hiccupping is still poorly
understood. Hiccups are classified under three categories
depending on their duration: acute, persistent, and* Correspondence: zhangshuangyan2014@163.com
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unless otherwise stated.intractable hiccups. Acute hiccups are defined as a hic-
cupping episode that lasts for minutes to hours; persis-
tent hiccups last for more than 48 hours; and intractable
hiccups last for more than 1 month. Hiccups are not
only confined to adults but are also observed among
infants [3,4] and children [5].
Stroke patients experience a variety of symptoms and
complications that can significantly impair their quality
of life. Some of the most commonly encountered compli-
cations in clinical practice include pressure ulcers [6-8],
depression [9], motor disability [10], insomnia [11], and
hiccups [12].
A wide range of pharmacologic interventions has been
used to treat persistent and intractable hiccups, such as
baclofen [13-15], gabapentin [16], chlorpromazine [17],
haloperidol [18], and metoclopramide [19]. Several cli-
nical studies have reported that baclofen may help treatLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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though a Cochrane systematic review found no sufficient
evidence for the treatment of persistent or intractable
hiccups with either pharmacologic or nonpharmacologic
interventions, all four studies included in the review had
focused on acupuncture, and not baclofen, or even other
pharmacologic interventions [20]. To the best of our
knowledge, only a few randomized controlled trials with
small sample sizes have evaluated the efficacy of baclofen
for persistent hiccups after stroke.
We conducted a randomized, double-blind, placebo-
controlled, 5-day clinical trial to evaluate the possible
benefit of baclofen in treating persistent hiccups after
stroke. We primarily hypothesized that baclofen is super-
ior to placebo for stroke patients with persistent hiccups.
Methods
Study design
This study was a two-parallel arm, blinded, randomized
controlled trial. The trial was conducted in accordance
with the Declaration of Helsinki and the Guidelines for
Good Clinical Practice at the Evidence-Based Medicine
Center of the Fourth Affiliated Hospital of Harbin Medical
University, a clinical research center in China. Patients
were recruited between August 2012 and November 2013.
The study was approved by the Medical Ethics Committee
of the Fourth Affiliated Hospital of Harbin Medical
University. Eligible participants were randomly allocated
to the baclofen group or the placebo group at a 1:1 allo-
cation ratio and received treatment for 5 days, with 15 days
of follow-up. This study complied with CONSORT
guidelines.
Inclusion and exclusion criteria
We included participants aged 18 to 65 years with persist-
ent hiccups (more than 48 hours but less than 1 month)
after stroke. In addition, participants were required not to
have taken baclofen within 15 days before study entry and
were required to sign an informed-consent form.
The exclusion criteria included persistent hiccups mainly
associated with cancer [21], multiple sclerosis [22], menin-
gitis [23], brain abscess [24], traumatic brain injury [1],
encephalitis [25], spinal cord lesions [26], kidney failure
[27], pneumonia [28], laryngitis [29], and cardiorespiratory
arrest [30]; rejection of baclofen therapy; and failure to
complete clinical treatment.
Randomization
Randomization was performed by using a computer, and
group-allocation instructions were concealed in opaque
sealed envelopes. For assignment to the baclofen or
placebo group, participants were required to select one
of the sequentially numbered envelopes.Participants and recruitment
We planned to conduct our research in the Fourth
Affiliated Hospital of Harbin Medical University. In
preparing for this research, we found that this center
had offered baclofen or placebo treatment to 30 people
between August 2012 and November 2013. This enabled a
fair test of the feasibility criteria, and if recruitment was
good, potentially permitted a reliable calculation of the
effect size of the intervention for computing the subse-
quent sample size. Those individuals who elected to
undergo baclofen treatment were informed about the re-
search and given an information sheet. From those
agreed to participate, consent was given at the next ap-
pointment. After the clinical assessment, participants
were randomized to receive baclofen or a placebo, both
of which were given by therapists, who were trained in
their administration.Intervention
Participants recruited to the baclofen group received
10 mg 3 times daily for 5 days. Participants assigned to
the placebo group received 10 mg of a placebo 3 times
daily for 5 days. The participants were then asked to
identify any obstacles to the goal attainment and to
consider the possibility that the therapy could help them
overcome these obstacles. This was intended to motivate
the participants to engage in the therapy.
The placebo tablets used in this study were composed
of hydroxypropyl cellulose, pregelatinized starch, dex-
trin, starch, silicon dioxide, magnesium stearate, sodium
carboxymethyl starch, sucrose, talcum powder, gelatin,
silicone oil, and Chinese wax. The tablets were produced
by Changzhou Siyao Pharmaceuticals Co. Ltd. and had
the same dose, taste, and color as baclofen.Assessments
Patients outcomes were evaluated by using the Chinese
Medicine Medical Association standard criteria [12] and
classified as follows: cure, cessation of persistent hiccups
within the intervention period, with no relapse in one
week; improvement, reduction in the frequency and seve-
rity of hiccups and other symptoms (such as abdominal
discomfort); and no effect, no amelioration of hiccups.Data collection and analysis
In addition to the clinical outcomes, the efficacy and side
effects in the two groups were recorded and analyzed. We
collected data on the number of eligible participants with
persistent hiccups, willingness of the participants to be
randomized, and compliance with the intervention, and
aimed to estimate the effect size for a fully powered trial.
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This feasibility study estimated that a sample of 30 par-
ticipants would be sufficient to provide data to answer
our study questions [31]. Clinical outcome data were
analyzed by using an “intention-to- treat” approach, and
the initial analysis examined the demographic and base-
line characteristics of patients randomized to the trial.
Between-group differences in categoric data were assessed
by using the Fisher Exact test or Mann–Whitney U test;
the t test was used for continuous data. Relative risks and
95% confidence intervals were also reported. Levels of
significance were reported at P < 0.05. Descriptive statistics
were used to assess the feasibility questions. Analysis was
performed by a statistician who was blinded to the study
group.
Results
In this study, 147 participants were initially screened. Of
these 147 people, 34 subjects were excluded because of
the following: cancer (eight patients), multiple sclerosis
(11 patients), spinal cord lesions (four patients), trau-
matic brain injury (eight patients), and meningitis (three
patients). The remaining 113 patients were entered into
the study. Of these 113 patients, 65 did not meet study
criteria (34 patients had acute hiccups, and 31 patients
had intractable hiccups), and 18 declined to participate
(five patients refused baclofen; 13 patients failed to
complete treatment). Therefore, 30 individuals were
randomized into the study. All 30 participants com-
pleted the study and were included in the final analysis
(Figure 1).Assessed for eligibility (n =
Randomized (n = 30)
       Treatment  group
- Allocated to baclofen  (n = 15)
- Discontinued intervention  (n = 0)




































Follow-up (n = 15)
Lost to follow-up  (n = 0)
Analyzed (n = 15)
Participants screened (n =
Figure 1 Flow chart of participants through the trial.The characteristics of the study sample are presented
in Table 1. The two groups did not differ significantly in
the majority of sociodemographic and clinical variables
investigated at the baseline. At the baseline, the mean
age was 60.38 ± 19.61 years in the baclofen group and
58.64 ± 18.57 years in the placebo group. The duration
of hiccups was 59.24 ± 9.65 hours and 61.32 ± 10.34 hours
in the baclofen group and placebo group, respectively. All
patients had a history of stroke. In the baclofen group, 10
and five patients had had ischemic and hemorrhagic
strokes, respectively, whereas in the placebo group, nine
and six participants had had ischemic and hemorrhagic
strokes, respectively. The ischemic and hemorrhagic
strokes had occurred 3.71 ± 1.28 months and 3.83 ±
1.35 months ago, respectively, in the baclofen group,
and 3.65 ± 1.32 months and 3.87 ± 1.39 months ago,
respectively, in the placebo group. The Fugl–Meyer
Assessment (FMA), modified Barthel Index (MBI), and
Neurological Deficit Scale (NDS) scores were 49.56 ±
21.67, 50.97 ± 24.15, and 15.12 ± 5.89, respectively, in
the baclofen group, and 51.21 ± 23.11, 52.24 ± 23.53, and
13.96 ± 5.77, respectively, in the placebo group.
An analysis of the clinical outcomes is presented in
Table 2. Fourteen participants in the baclofen group
were cured, compared with two in the placebo group
(RR, 7.00; 95% CI, 1.91–25.62; P = 0.003). One participant
in the baclofen group showed improvement in persistent
hiccups, compared with five patients in the placebo group
(RR, 0.20; 95% CI, 0.03–1.51; P = 0.12). None of the
patients in the baclofen group had no amelioration of the
hiccups, compared with eight patients in the placebo 113)
Excluded (n = 83)
-Not meeting inclusion criteria (n = 65)
•Acute hiccups (n = 34) 
•Intractable hiccups (n = 31)
-Declined to participate (n = 18)
•Refused baclofen (n = 5)
•Refused to complete treatment (n = 13)
   Control group
ocated to placebo (n = 15)
continued intervention  (n = 0)
Follow-up (n = 15)
Lost to follow-up  (n = 0)
Analyzed (n = 15)
 147)
Excluded (n = 34)
Underlying disease
- Cancer (n = 8)
- Multiple sclerosis (n = 11)
- Spinal cord lessions (n = 4)
- Traumatic brain injury (n = 8)
- Meningitis (n = 3)
Table 1 Baseline characteristics of participants at trial entry
Variable Group P value
Baclofen (n = 15) Placebo (n = 15)
Age Mean (SD) 60.38 (19.61) 58.64 (18.57) 0.78
Gender
Male 8 (53.33%) 9 (60.00%) 0.71
Female 7 (47.67%) 6 (40.00%) 0.71
Married 15 (100%) 14 (93.33%) 0.47
Ethnicity
Han Chinese 14 (93.33%) 13 (86.66%) 0.55
Other 0 (0.0%) 1 (6.67%) 0.49
Not recorded 1 (6.67%) 1 (6.67%) 1.00
Employment
Employed 2 (13.33%) 1 (6.67%) 0.55
Unemployed 1 (6.67%) 1 (6.67%) 1.00
Retired 12 (80.00%) 13 (86.66%) 0.63
Education
Completed high school 12 (80.00%) 13 (86.66%) 0.63
Completed tertiary education 3 (20.00%) 2 (13.34%) 0.63
Duration of hiccups (hours) Mean (SD) 59.24 (9.65) 61.32 (10.34) 0.51
Stroke
Ischemic 10 (66.67%) 9 (60.00%) 0.71
Hemorrhagic 5 (33.33%) 6 (40.00%) 0.71
Duration of stroke (months) Mean (SD)
Ischemia 3.71 (1.28) 3.65 (1.32) 0.90
Hemorrhage 3.83 (1.35) 3.87 (1.39) 0.94
Severity of stroke Mean (SD)
FMA 49.56 (21.67) 51.21 (23.11) 0.84
MBI 50.97 (24.15) 52.24 (23.53) 0.88
NDS 15.12 (5.89) 13.96 (5.77) 0.59
FMA, Fugl-Meyer Assessment; MBI, Modified Barthel Index; NDS, Neurological Defect Scale.
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a significant difference in efficacy was found between the
two groups (P < 0.01; Table 3).
No serious adverse events related to treatment were
documented, which might be due to the short treatment
duration. However, two patients in the baclofen group
reported mild side effects. One patient reported mild tran-









Hiccup cessation 14 2 7.00 (1.91–25.62) 0.003
Improvement 1 5 0.20 (0.03–1.51) 0.120
No effect 0 8 0.06 (0.00–0.94) 0.040Discussion
Our study provides data indicating that further evaluation
of baclofen is warranted in stroke patients with persistent
hiccups. Analysis of the clinical outcomes identified trends
in the cessation of persistent hiccups within the interven-
tion period; however, the numbers were too small, with
wide confidence intervals. The study demonstrated the ac-
ceptability of baclofen by the subjects, randomization, and
participation in the trial. Compliance and follow-up were






Baclofen 15 14 1 0
Placebo 15 2 5 8
Difference in efficacy between the two groups, P < 0.01.
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persistent hiccups among stroke patients and recruitment
at a single hospital site.
Our results suggest that 10 mg baclofen 3 times daily
is an acceptable dose, and concur with the findings of
Mirijello [13]. Both studies found that persistent hiccups
can be successfully treated with baclofen without any
significant side effects. Our study highlighted the need
for further research on the topic. Findings from the
physician interviews may not represent the views of all
clinicians at the host institution or be considered repre-
sentative of physicians elsewhere; however, our findings
indicate a supportive research culture for this topic of
study.
The side effects were generally well tolerated in this
study. No serious adverse events were recorded, and
only two patients reported mild side effects. One patient
reported mild transient drowsiness, and the other
reported mild dizziness. This low incidence of adverse
effects might be attributable to the short duration of the
study.
The study has several strengths. First, the trial was
randomized, thereby reducing selection bias. Second,
although no consensus was found on the optimal dose
of baclofen for persistent hiccups, our findings suggest
that the dose used in this study was in the therapeutic
range. However, the main limitation of the present study
is its size, and our findings should therefore be inter-
preted with caution.
The findings of this study will influence future deci-
sions concerning resources and planning for trials. We
consider that the randomization was acceptable, and we
will explore whether the window for eligibility can be
extended. An appropriate sample size has been deter-
mined to allow for attrition. Therefore, further studies
with larger numbers of patients receiving baclofen are
required to verify the results of this study.
Conclusions
The results of this study provide evidence to support the
hypothesis that baclofen may be of some use in treating
persistent hiccups. However, larger studies are warranted.
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